NEW YORK , Oct. 3, 2024 /PRNewswire/ -- Report on how AI is driving market transformation- The global enzyme-linked immunosorbent assay (elisa) market size is estimated to grow by USD 843.9 million from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of about 16.82% during the forecast period. Growing need for frequent diagnostic testing among aging population is driving market growth, with a trend towards growing importance of promotional activities.
However, lack of accessibility and affordability of diagnostic tests in developing countries poses a challenge. Key market players include Abbott Laboratories, Abcam plc, Agilent Technologies Inc., Amgen Inc.
, Avantor Inc., Becton Dickinson and Co., Bio Rad Laboratories Inc.
, bioMerieux SA, Cardinal Health Inc., Crux Biolabs Pty Ltd., Danaher Corp.
, Eppendorf SE, Illumina Inc., Lonza Group Ltd., Merck KGaA, Novo Nordisk AS, Perkin Elmer Inc.
, QIAGEN NV, Siemens Healthineers AG, and Thermo Fisher Scientific Inc.. AI-Powered Market Evolution Insights.
Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View your snapshot now Key Market Trends Fueling Growth The Enzyme-Linked Immunosorbent Assay (ELISA) market presents unique challenges for vendors due to its specialized nature and niche end-user base. Brand and product visibility play a limited role in sales, as technical expertise and distribution networks are prioritized. ELISA testing's intrica.